+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thrombosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851981
  • Report
  • July 2018
  • Region: Global
  • 252 pages
  • Transparency Market Research
1 of 2

Global Thrombosis Drugs Market: Overview

Thrombosis drugs help in the prevention or inhibition of thrombus, by mimicking the role of antithrombin, a protein molecule produced in the body, which helps clotting of the blood. Antithrombin is a small protein involved in the inactivation of several enzymes in the coagulation system. The global thrombosis drugs market is expanding at a significant pace due to factors such as increase in the cases of cancer and the number of patients consuming high amounts of tobacco, worldwide.

The global thrombosis drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, indication, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities have been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global thrombosis drugs market.

Global Thrombosis Drugs Market: Key Segments

Based on drug class, the global thrombosis drugs market can be segmented into factor Xa inhibitor, low molecular weight heparin, p2y12 platelet inhibitor, and others. The drug class in this segment have been analyzed based on different uses of drugs to treat thrombosis events in various regions. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. In terms of indication, the global thrombosis drugs market can be classified into pulmonary embolism, atrial fibrillation, deep vein thrombosis, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year.

Global Thrombosis Drugs Market: Regional Outlook

In terms of geography, the global thrombosis drugs market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year. The research study also provides the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the market and provides various attributes such as company overview, financial overview, drug class portfolios, business strategies, and recent developments. Major companies profiled in the thrombosis drugs market include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Thrombosis Drugs Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis - Thrombosis Drugs Market
4.4. Thrombosis Drugs Sales Analysis
4.5. Thrombosis Drugs Market Value Chain Analysis
4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2016-2026
4.6.1. Market Revenue Projection (US$ Mn)
4.6.2. Market Outlook
4.7. Key Trends

Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
5.1. Key Findings/Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drug Class, 2017-2026
5.3.1. Factor Xa Inhibitor
5.3.2. Low Molecular Weight Heparin
5.3.3. P2Y12 Platelet Inhibitor
5.3.4. Others
5.4. Market Attractiveness, by Drug Class

Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Indication, 2017-2026
6.3.1. Pulmonary Embolism
6.3.2. Atrial Fibrillation
6.3.3. Deep Vein Thrombosis
6.3.4. Others
6.4. Market Attractiveness, by Indication

Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Distribution Channel, 2017-2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Thrombosis Drugs Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017-2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Drug Class, 2017-2026
9.3. Market Value Forecast, by Drug Class, 2016-2026
9.3.1. Factor Xa Inhibitor
9.3.2. Low Molecular Weight Heparin
9.3.3. P2Y12 Platelet Inhibitor
9.3.4. Others
9.4. Market Value Share Analysis, by Indication, 2017-2026
9.5. Market Value Forecast, by Indication, 2016-2026
9.5.1. Pulmonary Embolism
9.5.2. Atrial Fibrillation
9.5.3. Deep Vein Thrombosis
9.5.4. Others
9.6. Market Value Share Analysis, by Distribution Channel, 2017-2026
9.7. Market Value Forecast, by Distribution Channel, 2016-2026
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Drug Class
9.8.3. By Indication
9.8.4. By Distribution Channel

Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017-2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Drug Class, 2017-2026
10.3. Market Value and Volume Forecast, by Drug Class, 2016-2026
10.3.1. Factor Xa Inhibitor
10.3.2. Low Molecular Weight Heparin
10.3.3. P2Y12 Platelet Inhibitor
10.3.4. Others
10.4. Market Value Share Analysis, by Indication, 2017-2026
10.5. Market Value Forecast, by Indication, 2016-2026
10.5.1. Pulmonary Embolism
10.5.2. Atrial Fibrillation
10.5.3. Deep Vein Thrombosis
10.5.4. Others
10.6. Market Value Share Analysis, by Distribution Channel, 2017-2026
10.7. Market Value Forecast, by Distribution Channel, 2016-2026
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Drug Class
10.8.3. By Indication
10.8.4. By Distribution Channel

Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017-2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Share Analysis, by Drug Class, 2017-2026
11.3. Market Value and Volume Forecast, by Drug Class, 2016-2026
11.3.1. Factor Xa Inhibitor
11.3.2. Low Molecular Weight Heparin
11.3.3. P2Y12 Platelet Inhibitor
11.3.4. Others
11.4. Market Value Share Analysis, by Indication, 2017-2026
11.5. Market Value Forecast, by Indication, 2016-2026
11.5.1. Pulmonary Embolism
11.5.2. Atrial Fibrillation
11.5.3. Deep Vein Thrombosis
11.5.4. Others
11.6. Market Value Share Analysis, by Distribution Channel, 2017-2026
11.7. Market Value Forecast, by Distribution Channel, 2016-2026
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis
11.8.1. By Country
11.8.2. By Drug Class
11.8.3. By Indication
11.8.4. By Distribution Channel

Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017-2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Share Analysis, by Drug Class, 2017-2026
12.3. Market Value and Volume Forecast, by Drug Class, 2016-2026
12.3.1. Factor Xa Inhibitor
12.3.2. Low Molecular Weight Heparin
12.3.3. P2Y12 Platelet Inhibitor
12.3.4. Others
12.4. Market Value Share Analysis, by Indication, 2017-2026
12.5. Market Value Forecast, by Indication, 2016-2026
12.5.1. Pulmonary Embolism
12.5.2. Atrial Fibrillation
12.5.3. Deep Vein Thrombosis
12.5.4. Others
12.6. Market Value Share Analysis, by Distribution Channel, 2017-2026
12.7. Market Value Forecast, by Distribution Channel, 2016-2026
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
12.8. Market Attractiveness Analysis
12.8.1. By Country
12.8.2. By Drug Class
12.8.3. By Indication
12.8.4. By Distribution Channel

Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017-2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Drug Class, 2017-2026
13.3. Market Value and Volume Forecast, by Drug Class, 2016-2026
13.3.1. Factor Xa Inhibitor
13.3.2. Low Molecular Weight Heparin
13.3.3. P2Y12 Platelet Inhibitor
13.3.4. Others
13.4. Market Value Share Analysis, by Indication, 2017-2026
13.5. Market Value Forecast, by Indication, 2016-2026
13.5.1. Pulmonary Embolism
13.5.2. Atrial Fibrillation
13.5.3. Deep Vein Thrombosis
13.5.4. Others
13.6. Market Value Share Analysis, by Distribution Channel, 2017-2026
13.7. Market Value Forecast, by Distribution Channel, 2016-2026
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Attractiveness Analysis
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Indication
13.8.4. By Distribution Channel

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
14.1.2. Baxter International, Inc.
14.2. Company Profiles
14.2.1. GlaxoSmithKline plc.
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Baxter International, Inc.
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Johnson & Johnson
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Bayer AG
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Sanofi
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Bristol-Myers Squibb Company
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. AstraZeneca plc
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Pfizer, Inc.
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Boehringer Ingelheim GmbH
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Aspen Pharmacare Holdings Limited
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll